research use only
Cat.No.S6476
| Related Targets | PD-1/PD-L1 CXCR STING AhR CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor |
|---|---|
| Other Immunology & Inflammation related Inhibitors | Cl-amidine Bestatin (Ubenimex) Bindarit (AF 2838) Tempol Tranilast GI254023X (GI4023) Sinomenine Geniposidic acid CORM-3 Germacrone |
|
In vitro |
DMSO
: 60 mg/mL
(198.37 mM)
Ethanol : 60 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 302.45 | Formula | C20H30O2 |
Storage (From the date of receipt) | 2 years -20°C liquid |
|---|---|---|---|---|---|
| CAS No. | 10417-94-4 | -- | |||
| Synonyms | Timnodonic Acid | SMILES | CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O | ||
Read more about storage stability stock solution CAS number SMILES
(data from https://clinicaltrials.gov, updated on 2026-02-27)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07261423 | RECRUITING | Childhood Asthma; Asthma Control; Asthma Exacerbation; Air Pollution, Risk Reduction Behaviors |
University of Pittsburgh |
2026-02-24 | |
| NCT07575438 | NOT_YET_RECRUITING | Type 2 Diabetes; Prediabetes (Insulin Resistance, Impaired Glucose Tolerance); Prediabetes / Type 2 Diabetes; Obesity & Overweight; Obesity and Diabetes Mellitus, Type 2 |
May Faraj, PDt, PhD |
2026-07 | PHASE2 |
| NCT06933095 | RECRUITING | Eldery People; Cognitive Decline; Memory Decline; DHA CNS Delivery |
University of Cincinnati |
2024-09-15 | |
| NCT06736925 | RECRUITING | Subconcussive Head Impact; Omega-3 Fatty Acids |
Indiana University |
2025-02-28 | |
| NCT00682318 | ACTIVE_NOT_RECRUITING | Healthy |
Carsten Skarke, MD |
2008-05 | |
| NCT07462013 | RECRUITING | Major Depressive Disorder (MDD) |
National Science and Technology Council, Taiwan |
2025-10-01 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.